Financial Statements · From SEC 10-K & 10-Q XBRL Filings
Apellis Pharmaceuticals Inc. Revenue & Financial Statements
Apellis Pharmaceuticals Inc. reported revenue of $1.0B for the fiscal year ended December 31, 2025, up 28.5% year over year, with net income of $22.4M and diluted EPS of $0.20.
- Company
- Apellis Pharmaceuticals Inc. APLS · NASDAQ
- Latest fiscal year
- FY ended Dec 31, 2025
- Statements
- Income · Balance Sheet · Cash Flow — 5 fiscal years, 8 quarters
Income Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 66.6M | 75.4M | 396.6M | 781.4M | 1.0B |
| Cost of revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | (536.3M) | (594.6M) | (517.1M) | (165.0M) | 55.4M |
| Pretax income | (431.3M) | (568.7M) | (478.0M) | (174.0M) | 144.6M |
| Net income | (748.3M) | (651.0M) | (531.3M) | (197.6M) | 22.4M |
| Diluted EPS | — | -6.15 | -4.45 | -1.60 | 0.20 |
| EBITDA | (534.9M) | (593.1M) | (515.3M) | (163.2M) | 57.0M |
Quarterly
| USD | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 172.3M | 199.7M | 196.8M | 212.5M | 166.8M | 178.5M | 458.6M | 199.9M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | (62.1M) | (29.4M) | (47.3M) | (26.2M) | (83.3M) | (33.3M) | 223.2M | (51.1M) |
| Pretax income | (66.3M) | (37.5M) | (56.9M) | (36.1M) | (91.9M) | (41.7M) | 216.3M | (58.6M) |
| Net income | (66.4M) | (37.5M) | (57.2M) | (36.5M) | (92.0M) | (41.7M) | 215.9M | (59.0M) |
| Diluted EPS | -0.54 | -0.30 | -0.46 | -0.29 | -0.74 | -0.33 | 1.67 | -0.45 |
| EBITDA | (61.6M) | — | (46.8M) | (25.7M) | (82.9M) | — | 223.5M | (50.8M) |
Balance Sheet
Fiscal year-end snapshots. Values in USD.
| USD | FY2020 | FY2021 | FY2022 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total assets | 960.6M | 881.8M | 760.2M | 885.1M | 1.1B |
| Current assets | 917.2M | 824.0M | 719.5M | 789.0M | 1.0B |
| Cash & equivalents | 565.8M | 640.2M | 551.8M | 411.3M | 466.2M |
| Total liabilities | 756.0M | 683.1M | 590.3M | 656.5M | 705.1M |
| Current liabilities | 128.3M | 131.8M | 167.6M | 185.5M | 323.6M |
| Long-term debt | — | — | 92.7M | — | — |
| Total debt | — | — | 92.7M | — | — |
| Stockholders’ equity | 204.6M | 198.7M | 169.9M | 228.5M | 370.1M |
| Net debt | — | — | (459.1M) | — | — |
Cash Flow Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | (563.1M) | (513.7M) | (594.7M) | (87.9M) | 45.3M |
| Investing cash flow | 247.6M | 59.9M | (674K) | (403K) | (313K) |
| Financing cash flow | 392.2M | 365.7M | 394.5M | 149.2M | 8.9M |
| Capital expenditure | 1.1M | 1.5M | 773K | 403K | 313K |
| Free cash flow | (564.2M) | (515.3M) | (595.5M) | (88.3M) | 45.0M |
| Dividends paid | — | — | — | — | — |
| Stock-based compensation | 70.7M | 91.1M | 105.9M | 114.1M | 104.0M |
Figures are parsed from SEC XBRL company facts and may be derived where issuers report year-to-date values (quarterly figures differenced; Q4 computed as FY minus Q3). Fiscal periods follow each company's fiscal calendar, not calendar years. Historical fact, not investment advice — verify with official SEC filings.
Every APLS filing, connected
Financials beside price, insider trades, and 8-K events — with alerts the moment something new is filed.